( MENAFN - GlobeNewsWire - Nasdaq) SUNNYVALE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co.
(Nasdaq: ME) (the“Company” or“23andMe”), a leading human genetics and preventive health company, today announced that the Company has regained compliance with the minimum closing bid price requirement under nasdaq Listing Rule 5550(a)(2) and the majority independent board and various board committee requirements under Nasdaq Listing Rule 5605. Accordingly, the Company's Class A common stock will continue to be listed on The Nasdaq Capital market and trade under the symbol“ME”. About 23andMe 23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future.
For more information, please visit . Contact [email protected] investors@23andme.
com Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words“believes,”“anticipates,”“estimates,”“plans,”“expects,”“intends,”“may,”“could,”“should,”“potential,”“likely,”“projects,”“predicts,”“continue,”“will,”“schedule,” and“would” or, in each case, their negative or other variations or comparable terminology,.
